Percutaneous Transcatheter Heart Valve Implantation in a Bicuspid Aortic Valve

Chiam, Paul T.L.; Chao, Victor; Tan, Swee-Yaw; Koh, Tian-Hai; Lee, Chung-Yin; Tho, Ving-Yuen See; Sin, Yoong-Kong; Chua, Yeow-Leng

doi:10.1016/j.jcin.2009.11.024

Cited by 57 publications

(33 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensitivity analyses were performed to test the stability of quantitative synthetic results. Publication bias was further assessed Of these, a total of 17 articles including 166 BAV patients met our inclusion criteria [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] (see Fig. 1).…”

Section: Included Studiesmentioning

confidence: 99%

Efficacy and Safety of Transcatheter Aortic Valve Implantation for Bicuspid Aortic Valves: A Systematic Review and Meta-Analysis

Xie

Shi

Xun

et al. 2016

ATCS

View full text Add to dashboard Cite

Section: Included Studiesmentioning

confidence: 99%

Efficacy and Safety of Transcatheter Aortic Valve Implantation for Bicuspid Aortic Valves: A Systematic Review and Meta-Analysis

Xie

Shi

Xun

et al. 2016

ATCS

View full text Add to dashboard Cite

“…1) Therefore, only a few reports regarding TAVR for a patient with a BAV have been presented. [1][2][3][4][5] However, those describe relatively acceptable outcomes in high-risk patients with BAV-related stenosis. For example, Wijesinghe, et al reported 11 patients with symptomatic severe BAV stenosis who underwent TAVR successfully at 3 Canadian tertiary hospitals.…”

Section: Commentmentioning

confidence: 99%

“…Because a bicuspid aortic valve (BAV) is generally included among those exclusion criteria, only sporadic cases of TAVR for patients with a BAV are found in recent reports. [1][2][3][4][5] . Here, we report successful TAVR for an 84-year-old man with severe aortic valve stenosis and a BAV.…”

Section: Introductionmentioning

confidence: 99%

Successful Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve

Maeda¹,

Kuratani²,

Torikai³

et al. 2014

ATCS

View full text Add to dashboard Cite

Transcatheter aortic valve replacement (TAVR) for patients with a bicuspid aortic valve (BAV) is challenging as the extent and location of valve calcification as well as bulky leaflets and an enlarged root may increase the risk of transcatheter heart valve (THV) displacement, distortion, or malfunctioning. We report successful TAVR for an 84-year-old man with a BAV. The THV was implanted closer to the aorta than usual to avoid spreading of the bulky leaflets over the THV outflow. Following implantation, there was trivial paravalvular leakage, with no distortion or malfunction detected.

show abstract

“…Additionally, the operator must be more vigilant when assessing for paravalvular leaks and must take into account the higher risk of ascending aorta dissection, particularly in cases of a dilated ascending aorta. 30 • Degree of angulation between the aorta and the heart can make accurate positioning more demanding, particularly in instances of a horizontal aortic root with a vertical aortic annulus.…”

Section: Assessment Of Cardiac Anatomymentioning

confidence: 99%

Transcatheter Aortic Valve Implantation

Al‐Lamee

Godino

Colombo

2011

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

S urgical aortic valve replacement (AVR) is the conventional treatment for severe aortic stenosis (AS). However, a high operative mortality of 7% to 10% is well recognized in high-risk groups. 1,2 Risk of AVR is increased by a number of factors, including increasing age, and comorbidities, such as heart failure, respiratory and renal disease, prior cardiac surgery, and need for concomitant coronary revascularization. 3 As a result, 30% to 40% of elderly patients do not have surgery because of 1 or more of the following reasons: (1) The patient is not referred for AVR by the cardiology team, (2) the patient is not accepted for an operation by the cardiothoracic team, and (3) the patient declines AVR. 4,5 Additionally, surgery is more likely to be denied in patients who are elderly and who have left ventricular (LV) dysfunction or multiple comorbidities 5 and is contraindicated in cases of porcelain aorta, radiation dermatitis, and liver cirrhosis. 6 However, conservative management of patients with severe AS is known to have a poor prognosis. 7 Transcatheter aortic valve implantation (TAVI) was developed to address this unmet need. After the demonstration of feasibility of TAVI in 2002, 8 it is now widely practiced, with Ͼ20 000 patients treated worldwide, and the technique has been recommended as an alternative strategy for patients in high-risk surgical groups. 9 Currently, there are 2 CE marked devices with some similar fundamental design features: the self-expanding CoreValve ReValving system (Medtronic Inc; Minneapolis, MN) and the balloon-expandable Edwards SAPIEN prosthesis (Edward Lifesciences Inc; Irvine, CA), which is now available as the new generation, smaller profile, balloonexpandable Edwards SAPIEN XT prosthesis. The CoreValve is available in 2 inflow diameter sizes, 26 and 29 mm, whereas the Edwards SAPIEN and Edwards SAPIEN XT valves are available in 23-and 26-mm diameters. Transfemoral, transapical, and transaxillary/subclavian delivery routes have been developed. Both the transfemoral and the transaxillary/subclavian routes involve a retrograde approach, whereas the transapical route involves an anterograde approach. More recently, the transaortic route also has been introduced, allowing direct aortic access. 10 The transfemoral route is the first choice for both prostheses in the majority of patients; however, in patients in whom the transfemoral route is contraindicated, the transapical route can be considered for Edwards SAPIEN or Edwards SAPIEN XT valve implantation, and the transaxillary/subclavian route is an alternative for implantation of the CoreValve.Multiple trials have assessed the efficacy of TAVI in terms of procedural success, early mortality, and short-term clinical outcomes. [11][12][13][14][15] More recently, medium-term outcomes have been reported for the Edwards SAPIEN, 16 with the longest published follow-up at 3 years 17 ; more comprehensive longterm survival data are awaited.Selection criteria have a crucial influence on complication rates and clinical outcomes after TA...

show abstract

Percutaneous Transcatheter Heart Valve Implantation in a Bicuspid Aortic Valve

Cited by 57 publications

References 1 publication

Efficacy and Safety of Transcatheter Aortic Valve Implantation for Bicuspid Aortic Valves: A Systematic Review and Meta-Analysis

Efficacy and Safety of Transcatheter Aortic Valve Implantation for Bicuspid Aortic Valves: A Systematic Review and Meta-Analysis

Successful Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve

Transcatheter Aortic Valve Implantation

Contact Info

Product

Resources

About